We believe that in ccRCC, this immunomodulatory effect of SLFN11 dominates the cancer-promoting mechanism and may mask the impact of its function in DNA damage response on current mainstream treatment options. The gene discussed is SLFN11; the disease is nonpapillary renal cell carcinoma.